Premature aging and neuropathic behaviours induced by an acute low-dose exposure to a sarin surrogate

Alexandre Champault1, Sarah Leterrier2, Rosalie Bel3

  • 1Department of Toxicology and Chemical Risks, Armed Forces Biomedical Research Institute, Bretigny sur Orge, France; Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Service Hospitalier Frédéric Joliot, Orsay, France.

Toxicology
|October 31, 2025
PubMed

Insights

Organophosphorus (OP) compound exposure, even at sublethal doses, can cause premature aging and long-term sensorimotor deficits in mice. This highlights the need to identify subtle intoxication signs for early intervention.

Area of Science:

  • Neuroscience
  • Toxicology
  • Aging Research

Background:

  • Organophosphorus (OP) compounds can cause acute cholinergic toxidrome.
  • Delayed neurological effects, like muscle weakness and sensory loss, are under-explored.
  • These symptoms resemble those in elderly individuals.

Purpose of the Study:

  • Investigate long-term sensorimotor effects of sublethal OP exposure.
  • Utilize a mouse model exposed to a sarin surrogate (NIMP).
  • Assess neurological, metabolic, and cellular changes over six months.

Main Methods:

  • Administered a 0.5 LD50 dose of 4-nitrophenyl isopropylmethylphosphonate (NIMP) to mice.
  • Conducted behavioral tests for locomotor and sensory function.
  • Measured acetylcholinesterase activity, performed PET and microCT scans, and used Luminex assays.

Main Results:

  • NIMP exposure caused mild intoxication without affecting weight.
  • Mice showed persistent muscle weakness and increased mechanical sensitivity.
  • Long-term effects included inhibited cortical acetylcholinesterase, altered brain metabolism, reduced bone density, and increased aging biomarkers.

Conclusions:

  • Sublethal NIMP exposure induces a premature aging phenotype in mice.
  • This leads to lasting sensorimotor impairments and neurometabolic disturbances.
  • Early identification of OP intoxication hallmarks is crucial, even in asymptomatic cases.

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...